Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: $IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Integra LifeSciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Integra LifeSciences Holdings's position in the market.
Integra LifeSciences Holdings reported first quarter 2024 financial results, with revenues of $368.9 million declining 3.1% on a reported basis and 2.5% on an organic basis compared to the prior year. GAAP earnings per share were $(0.04), while adjusted earnings per share were $0.55. The company completed the acquisition of Acclarent, Inc., updating full-year revenue guidance to a range of $1.672 billion to $1.687 billion.
Integra LifeSciences will showcase the CereLink® Intracranial Pressure (ICP) Monitoring System at the AANS Annual Scientific Meeting. The system offers advanced continuous ICP monitoring with minimal drift, MR conditional capability, durable sensors, and advanced data features. The relaunch addresses the important need for accurate ICP monitoring in managing brain injuries, strokes, and other conditions, demonstrating Integra's commitment to innovation and patient care.
